Clinical Case Report: Bullous Pemphigoid

International Journal of Medical Science

© 2024 by SSRG - IJMS Journal

Volume 11 Issue 1

Year of Publication : 2024

Authors : Juan Pablo Meza-Budani, Diana Ly-Liu, Ellen O’Riordan, Domingo Ly-Pen

10.14445/23939117/IJMS-V11I1P103

How to Cite?

Juan Pablo Meza-Budani, Diana Ly-Liu, Ellen O’Riordan, Domingo Ly-Pen, "Clinical Case Report: Bullous Pemphigoid," SSRG International Journal of Medical Science, vol. 11,  no. 1, pp. 11-13, 2024. Crossref, https://doi.org/10.14445/23939117/IJMS-V11I1P103

Abstract:

A patient diagnosed with Bullous Pemphigoid is presented. This is not a very frequent disease in Primary Care. Nevertheless, general practitioners or family physicians should be aware of this entity so as not to misdiagnose and make a suspicious and differential diagnosis. General practitioners or family physicians should also be aware of the follow-up and side effects of the specialist´s treatments.

Keywords:

Bullous pemphigoid, Dermatology vesicular lesion, Primary Care.

References:

[1] Loïc Vaillant et al., “Evaluation of Clinical Criteria for Diagnosis of Bullous Pemphigoid,” Archives of Dermatology, vol. 134, no. 9, pp. 1075-1080, 1998.
[CrossRef] [Google Scholar] [Publisher Link]
[2] Neil Korman, “Bullous Pemphigoid,” Journal of the American Academy of Dermatology, vol. 16, no. 5, pp. 907-924, 1987.
[CrossRef] [Google Scholar] [Publisher Link]
[3] M.S.M. Persson et al., “The Global Incidence of Bullous Pemphigoid: A Systematic Review and Meta-Analysis,” British Journal of Dermatology, vol. 186, no. 3, pp. 414-425, 2022.
[CrossRef] [Google Scholar] [Publisher Link]
[4] P.G. Stavropoulos, E. Soura, and C. Antoniou, “Drug-Induced Pemphigoid: A Review of the Literature,” Journal of the European Academy of Dermatology and Venereology, vol. 28, no. 9, pp. 1133-1140, 2014.
[CrossRef] [Google Scholar] [Publisher Link]
[5] Francesco Moro et al., “Bullous Pemphigoid: Trigger and Predisposing Factors,” Biomolecules, vol. 10, no. 10, pp. 1-28, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[6] Michael Kasperkiewicz, and Detlef Zillikens, “The Pathophysiology of Bullous Pemphigoid,” Clinical Reviews in Allergy and Immunology, vol. 33, pp. 67-77, 2007.
[CrossRef] [Google Scholar] [Publisher Link]
[7] George J. Giudice, Daryl J. Emery, and Luis A. Diaz, “Cloning and Primary Structural Analysis of the Bullous Pemphigoid Autoantigen BP180,” Journal of Investigative Dermatology, vol. 99, no. 3, pp. 243-250, 1992.
[CrossRef] [Google Scholar] [Publisher Link]
[8] Dennis A. Weigand, and Melissa K. Clements, “Direct Immunofluorescence in Bullous Pemphigoid: Effects of Extent and Location of Lesions,” Journal of the American Academy of Dermatology, vol. 20, no. 3, pp. 437-440, 1989.
[CrossRef] [Google Scholar] [Publisher Link]
[9] Bonnie D. Hodge et al., “The Spectrum of Histopathologic Findings in Pemphigoid: Avoiding Diagnostic Pitfalls,” Journal of Cutaneous Pathology, vol. 45, no. 11, pp. 831-838, 2018.
[CrossRef] [Google Scholar] [Publisher Link]
[10] Enno Schmidt, Rocco Dsella Torre, and Luca Borradori, “Clinical Features and Practical Diagnosis of Bullous Pemphigoid,” Dermatologic Clinics, vol. 29, no. 3, pp. 427-438, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[11] Giovanni Di Zenzo et al., “Bullous Pemphigoid: From the Clinic to the Bench,” Clinics in Dermatology, vol. 30, no. 1, pp. 3-16, 2012.
[CrossRef] [Google Scholar] [Publisher Link]
[12] Kiyoshi Nishioka et al., “Eosinophilic Spongiosis in Bullous Pemphigoid,” Archives of Dermatology, vol. 120, no. 9, pp. 1166-1168, 1984.
[CrossRef] [Google Scholar] [Publisher Link]
[13] Diya F. Mutasim, and Brian B. Adams, “Immunofluorescence in Dermatology,” Journal of the American Academy of Dermatology, vol. 45, no. 6, pp. 803-824, 2001.
[CrossRef] [Google Scholar] [Publisher Link]
[14] Denise Miyamoto et al., “Bullous Pemphigoid,” Brazilian Annals of Dermatology, vol. 94, no. 2, pp. 133-146, 2019.
[CrossRef] [Google Scholar] [Publisher Link]
[15] Valeryia Pratasava et al., “Bullous Pemphigoid and Other Pemphigoid Dermatoses,” Medicina, vol. 57, no. 10, pp. 1-14, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[16] Hywel C. Williams et al., “Doxycycline versus Prednisolone as an Initial Treatment Strategy for Bullous Pemphigoid: A Pragmatic, Non-Inferiority, Randomised Controlled Trial,” Lancet, vol. 389, no. 10079, pp. 1630-1638, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[17] Aslı Bilgiç Temel et al., “Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments,” Case Reports in Dermatology, vol. 9, no. 1, pp. 38-44, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[18] Pedro Miguel Garrido et al., “Emerging Treatments for Bullous Pemphigoid,” Journal of Dermatological Treatment, vol. 33, no. 2, pp. 649-661, 2022.
[CrossRef] [Google Scholar] [Publisher Link]
[19] Liuqi Zhao et al., “Evaluation of Dupilumab in Patients with Bullous Pemphigoid,” Jama Dermatology, vol. 159, no. 9, pp. 953-960, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[20] Elena Pezzolo, and Luigi Naldi, “Epidemiology of Major Chronic Inflammatory Immune-Related Skin Diseases in 2019,” Expert Review of Clinical Immunology, vol. 16, no. 2, pp. 155-166, 2020.
[CrossRef] [Google Scholar] [Publisher Link]